A study of dupilumab in Chinese patients with atopic dermatitis
نویسندگان
چکیده
Atopic dermatitis is a common skin condition in which the process of inflammation becomes imbalanced. Affected people have eczema‐like lesions and intense itching. Although mild atopic can be successfully treated with creams ointments, moderate severe disease often requires treatment corticosteroids immunosuppressants that affect entire body. However, these treatments cause undesirable side‐effects cannot used for long periods time.
منابع مشابه
prevalence of atopic dermatitis in children with type 1 diabetes mellitus in southeastern of iran (kerman province): a case-control study
چکیده ندارد.
15 صفحه اولCommon Allergens in Patients with Atopic Dermatitis
Abstract Background and objective: Being exposed to different allergens, followed by the production of specific IgE, has an important role in causing atopic dermatitis, recognizing the allergens and applying immunotherapy for treatment. We aimed to determine the frequency of common allergens in the patients suffering from atopic dermatitis. Material and Methods: In this descriptive- anal...
متن کاملAlopecia areata after dupilumab for atopic dermatitis
AA: alopecia areata AD: atopic dermatitis IL: interleukin Th: T helper INTRODUCTION Dupilumab is the first targeted biologic therapy approved for the treatment of atopic dermatitis (AD). More than 1,000 adult patient exposures formed the basis of its approval in March 2017 for the treatment of moderate-to-severe AD not well controlled with topical therapies or when other therapies are inadvisab...
متن کاملPrevalence of atopic dermatitis in patients with acne vulgaris
Background and Aim: Atopic dermatitis is a chronic inflammatory disease that is caused by an inflammatory process stimulated by Th2 cells. Acne vulgaris is a chronic inflammatory skin disease. It is associated with an increase in sebum secretion, unusual pilosebaceous keratinization and an increased inflammatory immune response. Propionibacterium acne can induce IL-17 production and Th1/Th17 re...
متن کاملDupilumab treatment in adults with moderate-to-severe atopic dermatitis.
BACKGROUND Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of these key drivers of type 2 helper T-cell (Th2)-mediated inflammation could help in the treatment of related diseases, including atopic dermatitis. METHODS We performed randomized, double-b...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Dermatology
سال: 2022
ISSN: ['1365-2133', '0007-0963']
DOI: https://doi.org/10.1111/bjd.21070